Treatments* | Observed mortality (%) and interactive response between treatments | |||||
---|---|---|---|---|---|---|
Second instar | χ 2 | Responsec | Third instar | χ 2 | Response*** | |
Tracer 800 ppm | 66.67 ± 6.67ab** | – | – | 43.33 ± 3.34ab** | – | – |
Tracer 400 ppm | 40.00 ± 5.77 cd | – | – | 23.33 ± 3.34bcde | – | – |
Tracer 200 ppm | 16.67 ± 6.67ef | – | – | 6.67 ± 3.33ef | – | – |
Sc 1000 IJs | 13.33 ± 3.33ef | – | – | 3.33 ± 3.33ef | – | – |
Sc 500 IJs | 3.33 ± 3.33ef | – | – | 0.00 ± 0.00f | – | – |
Sc 200 IJs | 0.00 ± 0.00f | – | – | 0.00 ± 0.00f | – | – |
Sc 100 IJs | 0.00 ± 0.00f | – | – | 0.00 ± 0.00f | – | – |
Hi 1000 IJs | 16.67 ± 6.6ef | – | – | 10.00 ± 5.77ef | – | – |
Hi 500 IJs | 6.67 ± 3.33ef | – | – | 3.33 ± 3.33ef | – | – |
Hi 200 IJs | 3.33 ± 3.33ef | – | – | 0.00 ± 0.00f | – | – |
Hi 100 IJs | 0.00 ± 0.00f | – | – | 0.00 ± 0.00f | – | – |
Sc + TR 800 ppm | 80.00 ± 5.77a | 39.69 | Synergistic | 50.00 ± 5.77a | 1.31 | Additive |
Sc + TR 400 ppm | 53.33 ± 3.33bc | 20.54 | Synergistic | 36.67 ± 6.67abc | 1.81 | Additive |
Sc + TR 200 ppm | 43.33 ± 3.34 cd | 54.92 | Synergistic | 16.67 ± 6.67 cdef | 1.54 | Additive |
Hi + TR 800 ppm | 76.67 ± 3.33a | 7.02 | Synergistic | 40.00 ± 5.77ab | 16.73 | Synergistic |
Hi + TR 400 ppm | 43.33 ± 3.34 cd | 12.1 | Synergistic | 33.33 ± 3.33abcd | 1.11 | Additive |
Hi + TR 200 ppm | 23.33 ± 6.67de | 1.87 | Additive | 13.33 ± 8.82def | 0.00 | Additive |
Control | 0.00 ± 0.00f | – | – | 0.00 ± 0.00f | – | – |